STRONG MEMORIAL HOSPITAL
- Type
- Teaching hospital
- Where
- ROCHESTER, NY
- Medicare CCN
- 330285
- Received
- $25,085,553 in 1,746 records, 2019 ($3,869,769 general, $21,215,784 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
- Lobbying client: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 473 | $3,869,769 |
| 2019 | Research payment | 1,273 | $21,215,784 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,273 | $21,215,784 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 46 | $1,538,487 |
| Grant | 50 | $705,927 |
| Royalty or License | 45 | $547,245 |
| Education | 29 | $492,921 |
| Consulting Fee | 28 | $229,259 |
| Space rental or facility fees (teaching hospital only) | 133 | $226,665 |
| Gift | 128 | $99,347 |
| Charitable Contribution | 14 | $29,914 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Intuitive Surgical, Inc. | $253,760 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $55,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $52,320 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $19,784 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Helsinn Therapeutics (U.S.), Inc. | $15,795 | Research payment | Cash or cash equivalent | AKYNZEO Drug, ONCOLOGY | Treatment of Refractory Nausea | 2019 |
| 2019-12-31 | Intuitive Surgical, Inc. | $13,600 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $12,170 | Research payment | In-kind items and services | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum Resistant Ovaria | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $10,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $10,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $9,555 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $3,469 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $2,438 | Research payment | Cash or cash equivalent | UR2018IPR990844Weinberg | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,910 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $1,379 | Research payment | Cash or cash equivalent | UR2019MRIPR992Kwok | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $1,231 | Research payment | In-kind items and services | A Platform Protocol for the Treatment of Relapsed /Refractory Aggressive Non-Hodgkin's Lymphoma | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $550 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $380 | Research payment | Cash or cash equivalent | UR2019MRIPR794Tawil | 2019 | |
| 2019-12-30 | TESARO, Inc. | $93,668 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-12-30 | TESARO, Inc. | $13,381 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-12-30 | Merck Sharp & Dohme LLC | $302 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-12-29 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-12-26 | United Therapeutics Corporation | $100,000 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | UNSPECIFIED RESEARCH PROJECTS | 2019 |
| 2019-12-26 | Halozyme Inc | $4,278 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Halozyme Inc | $4,278 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Halozyme Inc | $3,452 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Janssen Research & Development, LLC | $2,953 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2019 | |
| 2019-12-26 | Halozyme Inc | $2,605 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Halozyme Inc | $2,605 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Halozyme Inc | $1,850 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Merck Sharp & Dohme LLC | $1,542 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-12-26 | Amgen Inc. | $233 | Research payment | In-kind items and services | Otezla Biological, Inflammation | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. FOREMOST | 2019 |
| 2019-12-26 | Halozyme Inc | $101 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Halozyme Inc | $101 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-26 | Halozyme Inc | $101 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase | 2019 | |
| 2019-12-24 | PFIZER INC. | $126,415 | Research payment | Cash or cash equivalent | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY | 2019 | |
| 2019-12-24 | PFIZER INC. | $32,248 | Research payment | Cash or cash equivalent | DAURISMO Drug, ONCOLOGY | A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASD | 2019 |
| 2019-12-24 | Daiichi Sankyo Inc. | $31,588 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Savaysa Drug, Thrombosis | 2019 | |
| 2019-12-24 | Amgen Inc. | $2,808 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | GOULD | 2019 |
| 2019-12-24 | PFIZER INC. | $2,296 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2019 | |
| 2019-12-23 | Novo Nordisk Inc | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Ozempic Drug, Diabetes | 2019 | |
| 2019-12-20 | NeuroMetrix Inc | $16,126 | Research payment | Cash or cash equivalent | Quell Device, Pain Management | Quell Pain Management System for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathic Pain | 2019 |
| 2019-12-20 | Leadiant Biosciences, Inc. | $1,156 | Research payment | Cash or cash equivalent | ManNAc Biological, Neuromuscular Disease | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with G | 2019 |
| 2019-12-20 | Mallinckrodt Enterprises LLC | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CELLEX/XTS PHOTOPHERESIS SYSTEM Device, CRITICAL CARE | 2019 | |
| 2019-12-20 | Leadiant Biosciences, Inc. | $90 | Research payment | Cash or cash equivalent | ManNAc Biological, Neuromuscular Disease | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with G | 2019 |
| 2019-12-19 | Avanos Medical | $13,124 | Research payment | Cash or cash equivalent | COOLIEF* COOLED RADIOFREQUENCY Device, PAIN MANAGEMENT | A Prospective, Multi-center, Randomized, Assessor Blind, Controlled Study Comparing Lateral Branch Cooled Radiofrequency | 2019 |
| 2019-12-19 | Halozyme Inc | $8,634 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $3,705 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $3,170 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $3,170 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $2,046 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $2,046 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $2,046 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $2,046 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $1,560 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $1,400 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Merck Sharp & Dohme LLC | $1,300 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with R | 2019 |
| 2019-12-19 | Merck Sharp & Dohme LLC | $1,285 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-12-19 | Intercept Pharmaceuticals, Inc. | $842 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-19 | Regeneron Pharmaceuticals, Inc. | $588 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $500 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $206 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $206 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $100 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-19 | Halozyme Inc | $100 | Research payment | Cash or cash equivalent | A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisp | 2019 | |
| 2019-12-18 | Medtronic Vascular, Inc. | $29,492 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Investigator Sponsored Research | 2019 |
| 2019-12-18 | PFIZER INC. | $21,880 | Research payment | Cash or cash equivalent | A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY | 2019 | |
| 2019-12-18 | Intercept Pharmaceuticals, Inc. | $8,109 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $1,080 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2019 | |
| 2019-12-17 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-12-17 | Genentech, Inc. | $17,525 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY FOR MODERATE AD | 2019 |
| 2019-12-16 | Merck Sharp & Dohme LLC | $32,478 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-12-16 | Genentech, Inc. | $3,568 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $484 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-12-13 | Genentech, Inc. | $19,115 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-12-13 | Clovis Oncology, Inc. | $9,636 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-12-13 | Pharmacyclics LLC, an AbbVie Company | $583 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1145-LT | 2019 |
| 2019-12-13 | Pharmacyclics LLC, an AbbVie Company | $583 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1145-LT | 2019 |
| 2019-12-12 | Adamas Pharmaceuticals, Inc. | $1,322 | Research payment | Cash or cash equivalent | A 3-ARM MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADS-5102 AMANT | 2019 | |
| 2019-12-12 | Avanos Medical | $702 | Research payment | Cash or cash equivalent | COOLIEF* COOLED RADIOFREQUENCY Device, PAIN MANAGEMENT | A Prospective, Multi-center, Randomized, Assessor Blind, Controlled Study Comparing Lateral Branch Cooled Radiofrequency | 2019 |
| 2019-12-12 | Incyte Corporation | $127 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 | |
| 2019-12-12 | Incyte Corporation | $127 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 | |
| 2019-12-12 | Incyte Corporation | $127 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 | |
| 2019-12-12 | Incyte Corporation | $76 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $56,005 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | Pilot study to evaluate the Utility of equilibrium radionuclide angiography in Pulmonary Arterial Hypertension | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $9,100 | Consulting Fee | Cash or cash equivalent | ORENITRAM Drug, PAH | 2019 | |
| 2019-12-11 | Barco, Inc. | $6,250 | Gift | In-kind items and services | NIO C 2MP 21"2H2F EXCL DC Device, Diagnostic Imaging | 2019 | |
| 2019-12-11 | Barco, Inc. | $6,250 | Gift | In-kind items and services | NIO C 2MP 21"2H2F EXCL DC Device, Diagnostic Imaging | 2019 | |
| 2019-12-11 | Barco, Inc. | $6,250 | Gift | In-kind items and services | NIO C 2MP 21"2H2F EXCL DC Device, Diagnostic Imaging | 2019 | |
| 2019-12-11 | Barco, Inc. | $6,250 | Gift | In-kind items and services | NIO C 2MP 21"2H2F EXCL DC Device, Diagnostic Imaging | 2019 | |
| 2019-12-11 | Barco, Inc. | $6,250 | Gift | In-kind items and services | NIO C 2MP 21"2H2F EXCL DC Device, Diagnostic Imaging | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $2,506 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | Pilot study to evaluate the Utility of equilibrium radionuclide angiography in Pulmonary Arterial Hypertension | 2019 |
| 2019-12-11 | Roche TCRC, Inc. | $1,667 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $1,248 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | Pilot study to evaluate the Utility of equilibrium radionuclide angiography in Pulmonary Arterial Hypertension | 2019 |
| 2019-12-11 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,075 | Research payment | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | BENEFITS OF UCOR IN AMBULATORY DECOMPENSATED HEART FAILURE | 2019 |
| 2019-12-11 | Pharmacyclics LLC, an AbbVie Company | $1,000 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1140-IM | 2019 |
| 2019-12-11 | Pharmacyclics LLC, an AbbVie Company | $1,000 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1140-IM | 2019 |
| 2019-12-11 | Intercept Pharmaceuticals, Inc. | $775 | Research payment | Cash or cash equivalent | 1011507 | 2019 | |
| 2019-12-11 | GENZYME CORPORATION | $375 | Research payment | Cash or cash equivalent | LEMTRADA Drug, MULTIPLE SCLEROSIS | A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profi | 2019 |
| 2019-12-10 | PFIZER INC. | $37,335 | Research payment | Cash or cash equivalent | DAURISMO Drug, ONCOLOGY | A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASD | 2019 |
| 2019-12-10 | Merck Sharp & Dohme LLC | $877 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-12-10 | Kite Pharma, Inc. | $734 | Research payment | Cash or cash equivalent | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom | 2019 | |
| 2019-12-09 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-12-09 | TESARO, Inc. | $13,381 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-12-09 | GENZYME CORPORATION | $1,266 | Research payment | Cash or cash equivalent | LEMTRADA Drug, MULTIPLE SCLEROSIS | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-12-07 | PFIZER INC. | $20,432 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2019 | |
| 2019-12-07 | Merck Sharp & Dohme LLC | $2,680 | Research payment | Cash or cash equivalent | RSV Incidence and Hospitalization Associated Disability in Adults | 2019 | |
| 2019-12-06 | GW Research Limited | $18,145 | Research payment | Cash or cash equivalent | GWEP1415 | 2019 | |
| 2019-12-06 | Merck Sharp & Dohme LLC | $1,285 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-12-06 | GW Research Limited | $1,216 | Research payment | Cash or cash equivalent | GWEP1415 | 2019 | |
| 2019-12-05 | Genentech, Inc. | $40,271 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GANTENERUMAB IN EARLY AD | 2019 |
| 2019-12-05 | Bayer Healthcare Pharmaceuticals Inc. | $3,499 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 mHSPC | 2019 |
| 2019-12-05 | Abbott Laboratories | $2,698 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-12-05 | PFIZER INC. | $1,950 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 | |
| 2019-12-05 | Intercept Pharmaceuticals, Inc. | $1,827 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-04 | BioMarin Pharmaceutical Inc. | $5,450 | Research payment | Cash or cash equivalent | Kuvan Drug, PKU | PKU Demographics, Outcomes, and Safety Registry | 2019 |
| 2019-12-04 | KLS-Martin L.P. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-04 | MERZ NORTH AMERICA, INC. | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XEOMIN Biological, MUSCULOSKELETAL | 2019 | |
| 2019-12-03 | Clovis Oncology, Inc. | $12,432 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2019 |
| 2019-12-03 | PFIZER INC. | $1,123 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPI | 2019 | |
| 2019-12-02 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-12-02 | PFIZER INC. | $12,100 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-12-02 | Adamas Pharmaceuticals, Inc. | $1,398 | Research payment | Cash or cash equivalent | A MULTICENTER OPEN-LABEL SAFETY AND EFFICACY STUDY OF ADS-5102 AMANTADINE EXTENDED RELEASE CAPSULES IN PATIENTS WITH MUL | 2019 | |
| 2019-12-02 | Alkermes, Inc. | $1,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-01 | Merck Sharp & Dohme LLC | $98,951 | Research payment | Cash or cash equivalent | RSV Incidence and Hospitalization Associated Disability in Adults | 2019 | |
| 2019-11-29 | Janssen Research & Development, LLC | $6,415 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-11-28 | Regeneron Pharmaceuticals, Inc. | $1,552 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years | 2019 |
| 2019-11-27 | ABBVIE INC. | $1,427 | Research payment | Cash or cash equivalent | Skyrizi Biological, Immunology | M16-067 | 2019 |
| 2019-11-26 | Merck Sharp & Dohme LLC | $3,000 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with R | 2019 |
| 2019-11-26 | Medtronic USA, Inc. | $1,130 | Research payment | Cash or cash equivalent | RESTORE Device, Spinal Cord Neurostimulation | Vectors PM | 2019 |
| 2019-11-25 | Eli Lilly and Company | $300,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-11-25 | United Therapeutics Corporation | $30,230 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A PHASE III INTERNATIONAL MULTI-CENTER RANDOMIZED DOUBLE- BLIND PLACEBO-CONTROLLED CLINICAL WORSENING STUDY OF UT-15C IN | 2019 |
| 2019-11-25 | Merck Sharp & Dohme LLC | $27,065 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-11-25 | Merck Sharp & Dohme LLC | $2,314 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-11-25 | Smith+Nephew, Inc. | $1,560 | Research payment | Cash or cash equivalent | Birmingham Hip Resurfacing Device, Recon Hips | Birmingham Hip Resurfacing System BHR Post Approval Study US | 2019 |
| 2019-11-25 | Merck Sharp & Dohme LLC | $794 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-11-25 | Intercept Pharmaceuticals, Inc. | $791 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-11-25 | GENZYME CORPORATION | $442 | Research payment | Cash or cash equivalent | LEMTRADA Drug, MULTIPLE SCLEROSIS | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
| 2019-11-25 | Merck Sharp & Dohme LLC | $257 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2019 |
| 2019-11-22 | Merck Sharp & Dohme LLC | $4,800 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-22 | Olympus America Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Surgical Endoscopy Products | 2019 | |
| 2019-11-22 | PFIZER INC. | $1,004 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPI | 2019 | |
| 2019-11-22 | Verastem, Inc. | $505 | Research payment | In-kind items and services | Copiktra Drug, Hematology and Oncology | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | 2019 |
| 2019-11-22 | Regeneron Pharmaceuticals, Inc. | $250 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Neurocrine BioSciences, Inc. | $120,000 | Royalty or License | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | ABBVIE INC. | $5,318 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P11-282 | 2019 |
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $4,125 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $4,125 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $4,125 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $4,125 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $4,125 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Hill-Rom Company, Inc | $1,800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-11-21 | Davol Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | CSL Behring | $450 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $105 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-11-20 | Merck Sharp & Dohme LLC | $51,975 | Research payment | Cash or cash equivalent | ZONTIVITY Drug, CARDIOVASCULAR | TRA added to Tadalafil in Pneumonectomy,MCT Model of PAH | 2019 |
| 2019-11-20 | Merck Sharp & Dohme LLC | $41,580 | Research payment | Cash or cash equivalent | ZONTIVITY Drug, CARDIOVASCULAR | TRA added to Tadalafil in Pneumonectomy,MCT Model of PAH | 2019 |
| 2019-11-20 | Gilead Sciences, Inc. | $29,734 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2019 | |
| 2019-11-20 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16,382 | Research payment | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | BENEFITS OF UCOR IN AMBULATORY DECOMPENSATED HEART FAILURE | 2019 |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Incyte Corporation | $659 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Pharmacyclics LLC, an AbbVie Company | $583 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1145-LT | 2019 |
| 2019-11-20 | Pharmacyclics LLC, an AbbVie Company | $583 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1145-LT | 2019 |
| 2019-11-20 | Verastem, Inc. | $505 | Research payment | In-kind items and services | Copiktra Drug, Hematology and Oncology | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | 2019 |
| 2019-11-20 | Incyte Corporation | $461 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-11-20 | Bio-Rad Laboratories, Inc. | $34 | Gift | Cash or cash equivalent | Amplification Reagents Device, Amplification | 2019 | |
| 2019-11-19 | Merck Sharp & Dohme LLC | $98,951 | Research payment | Cash or cash equivalent | RSV Incidence and Hospitalization Associated Disability in Adults | 2019 | |
| 2019-11-19 | Incyte Corporation | $10,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-11-19 | Incyte Corporation | $4,975 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-11-19 | Incyte Corporation | $2,600 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-11-19 | Incyte Corporation | $2,175 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-11-19 | Genentech, Inc. | $2,021 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22 UC STUDY | 2019 |
| 2019-11-19 | Incyte Corporation | $1,950 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2019 | |
| 2019-11-18 | PFIZER INC. | $75,000 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | TOFACITINIB MEDIATED MODULATION OF AQUAPORIN 3 AQP3 EXPRESSIONS ON PATHOGENIC TYPE 17 CELLS IN PSORIATIC DISEASE | 2019 |
| 2019-11-18 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-11-18 | Agios Pharmaceuticals, Inc. | $12,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-18 | Janssen Research & Development, LLC | $7,958 | Research payment | Cash or cash equivalent | Protocol - 54757414-MMY-1001: An Open-label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monocl | 2019 | |
| 2019-11-18 | GENZYME CORPORATION | $6,468 | Research payment | Cash or cash equivalent | LEMTRADA Drug, MULTIPLE SCLEROSIS | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS034 | 2019 |
The latest 200 records of 1,746.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rochester, NY, county Monroe County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Rochester, NY | County Monroe County, NY | State New York |
|---|---|---|---|
| Population B01003 | 208,772 | 753,753 | 19,852,366 |
| Population, 2020 census P1 | 211,328 | 759,443 | 20,201,249 |
| Median age B01002 | 33.7 | 39.6 | 39.8 |
| Under 18 B01001 | 20.9% | 20.3% | 20.5% |
| 65 and over B01001 | 13.1% | 18.8% | 17.9% |
| Households B11001 | 93,261 | 318,428 | 7,722,646 |
| Foreign born B05002 | 8.2% | 7.9% | 22.8% |
| Median household income B19013 | $47,213 | $76,382 | $85,974 |
| Median family income B19113 | $57,673 | $102,166 | $106,873 |
| Per capita income B19301 | $31,314 | $44,107 | $50,712 |
| Poverty rate B17001 | 27.8% | 13.6% | 14.0% |
| Unemployment rate B23025 | 7.9% | 4.9% | 6.4% |
| Civilian labor force B23025 | 105,136 | 391,197 | 10,171,766 |
| Mean commute (minutes) B08013 | 19.3 | 19.9 | 32.6 |
| Bachelor's degree or higher B15003 | 30.0% | 41.5% | 40.2% |
| Housing units B25001 | 104,479 | 339,430 | 8,585,241 |
| Owner-occupied B25003 | 38.1% | 63.7% | 54.3% |
| Renters B25003 | 61.9% | 36.3% | 45.7% |
| Median home value B25077 | $139,600 | $213,700 | $423,800 |
| Median gross rent B25064 | $1,081 | $1,173 | $1,621 |
| White, not Hispanic B03002 | 36.4% | 67.7% | 52.8% |
| Black B03002 | 34.7% | 13.5% | 13.4% |
| Hispanic or Latino B03002 | 19.6% | 9.9% | 19.8% |
| Asian B03002 | 3.2% | 3.8% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rochester, NY.
Comments